Multiplex PCR
Simultaneous amplification and detection of multiple molecular targets in a single test. It is particularly useful when the decision depends on a defined set of pathogens, genes, variants or markers.

Target-defined testing
An approach in which the panel screens for already known targets. It differs from sequencing or exploratory metagenomics, which may be more suitable when the biological scope has not yet been defined.

Intended use
The intended use as stated by the manufacturer. In the context of IVDs and medical software, it defines the regulatory scope and limits what can be communicated as a claim.

Data governance
A set of rules, controls and responsibilities governing the collection, access, interoperability, security and primary or secondary use of health or diagnostic data.

Multiplex PCR diagnostics have entered a more mature phase. It is not enough to describe them simply as a ‘rapid’ technology or a growing market: for industry, scientific or financial stakeholders, it is important to understand where they generate value, what regulatory constraints they face, and into which workflows they can be integrated without creating additional complexity. The argument put forward in this article is deliberately cautious: multiplex PCR creates value when it makes a molecular decision on defined targets faster and more widely applicable. This definition rules out two common pitfalls. The first is market hype: CAGR, market size and commercial forecasts are not a sufficient basis for scientific-strategic insight. The second is scientific overclaim: multiplex PCR is not a universal discovery platform, but a powerful tool when the panel, intended use, performance and associated decision are clear. This shift in perspective is consistent with regulatory developments. In Europe, the IVDR and MDCG guidelines require attention to classification, intended purpose, performance evaluation, software and the quality of evidence. In the United States, the FDA treats multiplex NAAT panels as devices with specific risks, including analytical performance, controls, result interpretation and the role of instrumentation/software. [1][2][3] [4]

For Helyx Industries S.p.A., this framework leads to a more robust positioning: not simply ‘doing more PCR’, but building distributed, validatable and integrable molecular workflows. Within this architecture, Hyris oversees distributed and connected qPCR; Vytro is the most coherent solution for clinical PCR, IVD and deep multiplexing applications where the intended use, validation and regulatory requirements permit; Mytho extends the vision beyond PCR towards NGS, custom panels and bioinformatics pipelines. The group’s strength lies in the complementarity of its divisions, not in their amalgamation. [17][18][19][20][21]

Clinical applications in infectious diseases remain one of the most established areas for multiplex PCR. In A&E, intensive care, clinical microbiology and the management of hospital-acquired infections, the value lies not simply in ‘detecting more targets’, but in reducing the time between sample collection and a useful decision: isolation, lifting of isolation, targeted therapy, antibiotic de-escalation or the need for confirmation. The literature on multiplex testing confirms that clinical benefit depends on the workflow. A broad panel, on its own, does not automatically improve outcomes; it becomes useful when the result is available within the appropriate decision-making window and when the data is integrated with antimicrobial stewardship, clinical protocols and correct interpretation. The review by Serapide et al. highlights the role of multiplex PCR in the rapid diagnosis of bacterial and fungal infections and in the selection of antimicrobial therapy, but also points out limitations related to costs, training and implementation. [5]

This is where Vytro and Hyris can complement each other without overlapping. Vytro offers the most coherent framework for clinical applications, IVD kits and the design of multiplex panels intended for medical use, provided the product is supported by appropriate evidence and a sound regulatory pathway. Hyris is the technological platform capable of supporting distributed, connected and operationally replicable qPCR. In an insight aimed at partners and investors, the correct message is not ‘we bring everything everywhere’, but ‘we bring target-based tests where the result can influence a decision’. [17][18][19][21]

The nutraceutical sector is an interesting one, but also one of the most sensitive from an editorial perspective. Consumer products have often framed microbiota, probiotics and personalised nutrition in terms that go beyond the available evidence. This is why multiplex PCR must be positioned with precision. The only defensible claim is that a rapid microbiota test does not automatically lead to clinically validated personalised supplements.

Recent literature on microbiome testing in Europe, on the contrary, highlights significant issues: a faecal sample sent to six different providers yielded reports with conflicting results and interpretations; experts have pointed to over-promising, a lack of methodological transparency, limitations in reliability and as yet unproven clinical utility for many consumer recommendations. [15]

The most robust aspect of the nutraceutical sector lies elsewhere: ingredient authentication, species-specific verification, identification of adulteration, targeted testing of botanical raw materials, and monitoring of defined targets throughout the supply chain. In this context, a global survey of commercial herbal products analysed using DNA-based methods reported adulteration in 27 per cent of the products included; whilst this figure should not be taken as a universal claim, it confirms the importance of authenticity testing. [14]

Multiplex PCR may therefore have a role in the agri-food and nutraceutical sectors as a rapid quality control technology, rather than as a shortcut to personalised clinical claims. It is a less spectacular but far more robust approach: target-defined panels to identify declared species, known contaminants, authenticity markers or microorganisms of interest, integrated into QA/QC processes rather than into unvalidated consumer narratives. In terms of business divisions, this sector may involve Hyris as a distributed qPCR platform for near-line or at-line controls; Vytro only if the application falls within a clearly defined clinical/IVD scope; Mytho when the problem requires NGS, metagenomics, broad characterisation or advanced bioinformatics. The distinction is crucial: multiplex PCR for known targets, NGS/Mytho for more complex or exploratory biological contexts. [18][20]

Outside the hospital setting, one of the most tangible opportunities lies in industrial quality control. Food safety, biotech production, GMP environments and highly sensitive supply chains all share a common need: to reduce the lead time between sample collection, result and operational decision. Here too, multiplex PCR works best when the panel is built around defined targets and the result enables a binary or quasi-binary decision: release, hold, further investigation, confirmation. In the food sector, conventional methods for detecting pathogens can be slow and labour-intensive. The review by Law et al. describes rapid nucleic acid-based methods—including simple PCR, multiplex PCR and real-time PCR—as valuable tools for the detection of foodborne pathogens, whilst highlighting both the advantages and limitations of the various platforms. [13]

However, the industry must avoid one mistake: presenting multiplex PCR as a universal substitute for cultures, official methods or in-depth investigative analysis. Its most credible role is that of rapid triage, targeted screening or process control. If the result is positive, further confirmation or characterisation may be required; if it is negative, the value depends on sensitivity, sampling, matrix, detection limits and method validation. This approach is consistent with Hyris when the aim is to deploy testing capacity close to the production process; with Vytro when there is a need to develop robust, reproducible and potentially validatable assays for medical or regulated contexts; and with Mytho when the scope becomes broader: genomic characterisation, tracing, complex multi-target surveillance or analysis not limited to predefined targets. [18][19][20]

Environmental surveillance is one of the most interesting areas for the coming years, particularly when linked to wastewater surveillance, emerging pathogens, antimicrobial resistance and One Health. Here, multiplex PCR can be useful for monitoring known targets in distributed networks, whilst NGS and metagenomics become relevant when the aim is to explore broader signals or identify variants and complex microbial communities. The CDC describes wastewater monitoring as a useful tool for the early identification of outbreak trends, guiding prevention measures, providing additional insights into the spread of diseases and complementing other public surveillance data. [16]

Caution is required. Environmental data does not constitute an individual diagnosis; it is an aggregated signal, influenced by sampling, matrix, infrastructure, standardisation and comparability between sites. A distributed platform can increase the reach of monitoring, but its value depends on governance, standardisation and the ability to integrate the data into public or industrial decision-making systems.
For Helyx, the strongest narrative is a division of roles: Hyris enables target-based collection and distributed qPCR; Mytho can support the transition towards NGS, bioinformatics and deeper genomic analyses when the problem requires greater information density; Vytro remains focused on clinical value and IVD. From a One Health perspective, this architecture avoids confusing different tools and makes the group more credible in the eyes of scientific stakeholders. [17][18][19][20]

AI and the cloud are important components, but they must be discussed using precise language that is consistent with the regulated context of diagnostics. Terms such as ‘virtual biologist’ or ‘AI that makes decisions’ are misleading: the correct terminology is decision support, workflow automation, assisted interpretation, quality control, anomaly detection, traceability and human supervision.

The FDA, in its framework on AI in Software as a Medical Device, clarifies that AI/ML can transform medical devices but require management throughout their entire lifecycle, attention to modifications and appropriate regulatory pathways. [6] The FDA’s guidance on cybersecurity in medical devices also makes cyber resilience an element of design, labelling and pre-market documentation for devices with cyber risk. [7]

In Europe, the AI Act introduces horizontal obligations for high-risk AI systems, including those associated with regulated products, whilst the MDCG guidelines on medical software help to distinguish between generic software, medical device software and IVD software. [8][9][12] For a connected diagnostic ecosystem, the value of AI lies not in ‘monetising data’ or replacing professional judgement, but in improving the quality, consistency, auditability and timeliness of the workflow. It is an industrial and regulatory value even before it is a commercial one.

In connected diagnostics, data is not a raw material to be monetised indiscriminately: it is a sensitive asset, subject to regulation and governed by specific purposes, legal bases, data minimisation, security and the rights of the data subject. For this reason, the value of data must be defined in terms of governed analytics, process quality, aggregated monitoring and decision support, rather than as the direct or indiscriminate monetisation of data. The GDPR remains the general framework for the processing of personal data in Europe, whilst the European Health Data Space introduces a specific framework for the primary and secondary use of health data, with an emphasis on interoperability, controlled access, traceability and secure environments. [10][11]

The correct term, therefore, is ‘operational intelligence’: aggregated and governed analytics to improve quality, monitoring, network performance, maintenance, audit trails, trend monitoring and decision support. It is a far more defensible concept than the direct monetisation of data and aligns better with an industrial biotech group seeking to build trust over the long term. This distinction is strategic. Institutional and clinical partners are not looking for platforms that ‘exploit’ data: they are looking for systems that protect it, make it interoperable, use it to improve processes and enable audits. In a regulated market, trust is part of the product.

Business models, too, must be grounded in reality. “Diagnostics-as-a-Service” can only be a useful concept if it is translated into tangible mechanisms: hardware available for hire or on loan, pay-per-use schemes, reagent rental, service contracts, remote support, maintenance, training, controlled updates and quality management. Otherwise, it remains little more than unverifiable start-up jargon.

For multiplex diagnostics, there are three robust models. The first is the platform-consumables model, where the installed base generates recurring revenue from assays, reagents and services. The second is the OEM/co-development model, in which a partner integrates technology, assays or workflows into their own offering. The third is the managed service model, where the customer does not simply purchase an instrument, but a diagnostic service governed by SLAs, traceability and support.

These models are only credible if backed by measurable KPIs: end-to-end TAT, hands-on time, invalid/repeat rate, percentage of results that change a decision, cost per actionable episode, uptime, remote resolution time, completeness of the audit trail and rollout time for a new assay.

In other words: value is not demonstrated by market forecasts, but by verifiable operational and clinical metrics. For Helyx Industries, the potential advantage lies in being an integrated group, not a single, isolated technology. Hyris can support the scalability of distributed qPCR deployment; Vytro can cover clinical and IVD assays where the scope is defined; Mytho can extend the scope to NGS and bioinformatics when the opportunity requires greater molecular depth. [17][18][19][20]

The emerging opportunities offered by multiplex PCR diagnostics are real, but not all are equally well-established. The most robust applications are found where multi-target testing reduces decision-making time, improves clinical appropriateness and enables the standardisation of complex workflows. Infectious disease clinics, syndrome-based panels, antimicrobial stewardship, target-based food safety, industrial quality control and environmental biosurveillance represent concrete areas of application, provided that the scope of use is clearly defined and supported by appropriate validation. The weakest aspects, however, concern overly broad narratives: a hyper-growing market based on commercial sources; the consumer microbiome transformed into a clinical nutraceutical promise; autonomous AI; data monetisation; and DaaS models formulated without operational substance. Removing these elements does not weaken the article: it makes it more credible. The real opportunity for Helyx Industries S.p.A. lies in positioning itself as a group capable of integrating technology, application and data without blurring the boundaries between them. Hyris enables distributed and connected qPCR; Vytro translates clinical PCR and deep multiplexing into medical/IVD contexts where applicable; Mytho takes the group beyond PCR, towards NGS, custom panels and bioinformatics. This architecture allows molecular diagnostics to be presented not as a single product, but as a modular industrial infrastructure. [17][18][19][20][21]

The most credible market trend seems to be placing less and less value on generic promises and increasingly on platforms that demonstrate value in real-world workflows: less time wasted, faster decisions, better-governed data, more traceable quality and the ability to adapt to different verticals without compromising rigour. Multiplex PCR remains one of the key technologies in this transition, provided it is presented for what it really is: not a universal shortcut, but a driver of rapid molecular decision-making when the targets, context and governance are clear.